Norris Perne & French LLP MI Has $11.09 Million Holdings in Zoetis Inc. $ZTS

Key Points

• Norris Perne & French LLP MI has increased its stake in Zoetis Inc. by 4.1%, now holding 71,093 shares valued at approximately $11.09 million.
• Recent analyst ratings for Zoetis show mixed sentiment, with a downgrade from Leerink Partners to a "hold" rating, while Piper Sandler raised its price target from $210 to $215 with an "overweight" rating.
• Zoetis reported earnings of $1.76 per share, beating the consensus estimate, with revenues of $2.46 billion for the quarter, reflecting a year-over-year increase of 4.2%.

Norris Perne & French LLP MI increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 4.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,093 shares of the company's stock after purchasing an additional 2,804 shares during the period. Norris Perne & French LLP MI's holdings in Zoetis were worth $11,087,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. bought a new position in Zoetis during the first quarter worth about $25,000. 1248 Management LLC bought a new position in Zoetis during the first quarter worth about $27,000. Saudi Central Bank bought a new position in Zoetis during the first quarter worth about $29,000. Cornerstone Planning Group LLC lifted its holdings in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Finally, ORG Partners LLC lifted its holdings in Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company's stock worth $37,000 after acquiring an additional 84 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on ZTS. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Argus restated a "buy" rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Price Performance

NYSE:ZTS opened at $143.52 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock's 50-day simple moving average is $150.35 and its 200 day simple moving average is $155.64. The company has a market cap of $63.61 billion, a P/E ratio of 24.70, a P/E/G ratio of 2.30 and a beta of 0.88. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $197.51.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.